Manufacturers
Turn an asset into a franchise.
Value leaks when clinical, medical and commercial decisions are made in sequence instead of as one system. We carry them together.
The decisions we are brought in for
Questions clients actually arrive with.
A few examples. Choose one to see how we take it apart.
Development
Is the target product profile commercially meaningful?
What we look at
What the profile promises, set against what this market already pays for.
What often surfaces
A profile built to clear a trial is not the same as one built to win a chair.
What you get
The profile scored against the forces that decide adoption, with the weak claims named.
Evidence
Are the trials measuring what the market will value?
What we look at
Whether the endpoints map to something a provider or a patient will actually notice.
What often surfaces
Statistical significance and commercial significance are not the same claim.
What you get
An endpoint set that has to satisfy the agency and the market, judged against both.
Positioning
Can the differentiation survive outside the boardroom?
What we look at
How the claim holds once a competitor is in the room and the question gets hostile.
What often surfaces
Differentiation that exists only in a slide deck collapses at the first real objection.
What you get
One claim structure that holds from medical affairs through to the field.
Launch
What launch sequence creates sustainable adoption?
What we look at
Which audience has to believe it first, and what they need to see before they will.
What often surfaces
Sequence sets the ceiling more often than spend does.
What you get
A launch order with the dependencies between audiences made explicit.
Portfolio
How should the asset sit inside the portfolio?
What we look at
What the asset takes from, and gives to, everything else you already sell.
What often surfaces
Two products can both perform and still quietly cost each other.
What you get
A portfolio position with the trade-offs priced rather than assumed.
Lifecycle
What is the second act after launch?
What we look at
What is left to sell once the novelty of the launch is spent.
What often surfaces
The second act is usually decided long before the first one ships.
What you get
A lifecycle path that does not depend on another molecule arriving.
Representative deliverables
What actually lands on the table.
Every question runs through the same framework. What it returns is specific to the asset.
Commercial opportunity assessment
Size, shape and realistic ceiling of the opportunity.
Target product profile refinement
What the product must be to matter commercially.
Evidence and endpoint strategy
Measuring what the market will reward, not only what clears.
Positioning and message architecture
One claim structure that holds from medical to field.
Pricing and value strategy
What it is worth, and who gets to decide that.
Launch-readiness assessment
An honest read on what is not ready yet.
Medical-education strategy
Teaching the science the market has to believe.
Portfolio and lifecycle roadmap
Where the asset goes after its first good year.
Competitive response plan
What the incumbent does next, and what you do about it.
Scoped to the question. Most engagements produce two or three of these, not nine.
Who brings us in
Usually the person who owns the number.
- CEO
- Commercial leadership
- Marketing
- Business development
- Pipeline teams
- Medical affairs
Marga Intelligence™ applied
Run the framework forward, before the market runs it for you.
The same five forces that price an asset for an investor can shape it for a manufacturer. We score the asset early, find the weak force, and design the plan around it.
Explore Marga Intelligence →